Equillium, Inc. Gains 36.84%
Equillium, Inc. (EQ:NASDAQ) jumped higher at $1.56, a gain of 36.8%. On Thu, Aug 21, 2025, EQ:NASDAQ hit a New 2-Week High of $1.56. The stock got featured on our News Catalysts scanner on Sat, Aug 09, 2025 at 01:05 AM in the 'BIOTECH' category. From Thu, Aug 07, 2025, the stock recorded 60.00% Up Days and 36.36% Green Days
About Equillium, Inc. (EQ:NASDAQ)
Equillium Inc is a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, which is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.
Top 10 Gainers:
- Hempacco Co., Inc. (HPCO:NASDAQ), 350%
- Aptorum Group Limited (APM:NASDAQ), 234.65%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 97.3%
- Smart for Life, Inc. (SMFL:NASDAQ), 92.31%
- Gaxos.ai Inc. (GXAI:NASDAQ), 51.65%
- Luda Technology Group Limited (LUD:NYSEMKT), 49.89%
- SelectQuote, Inc. (SLQT:NYSE), 41.53%
- Sol-Gel Technologies Ltd. (SLGL:NASDAQ), 40.22%
- Tharimmune, Inc. (THAR:NASDAQ), 38.44%
- Equillium, Inc. (EQ:NASDAQ), 36.84%